Introduction
============

With the rapid progression of high-throughput (HT) -omic technologies (e.g., genomics, transcriptomics and proteomics), biological information has exploded over the past decade. These HT approaches allow scientific investigations to shift from traditional reductionism to systems biology approaches to study complex interactions in biological systems with a holistic perspective [@B1]. As simple intracellular organisms, viruses must hijack host factors to survive and propagate at multi-stages of their life cycles in the host. Viruses have developed a variety of delicate strategies to facilitate their invasion and replication/transcription of their genomes, while at the same time silencing host immune responses by manipulating host proteins and cellular processes. The systematic characterization of the viral proteome-host interactions, and the identification of new host targets, would be invaluable in the understanding of viral invasion and replication mechanisms in infectious diseases, autoimmune diseases, and cancer [@B2]. The findings from these studies will greatly facilitate the detection of viral infection and progression, antiviral drug discovery, and therapeutic treatment [@B3]-[@B5].

Through a profound effort from the ORFeome Collaboration, a large set of sequence-verified open reading frame (ORF) clone collections (bacteria, yeast, mouse, human) have been constructed and are accessible to the research community [@B6]-[@B14]. Interestingly, of the 2,000 viral genomes that have been sequenced, only a small fraction of viral ORFeome plasmids have been constructed, and the molecular mechanism of most of virus-host interactions is largely unknown [@B2]. Pellet *et al*. pioneered the ViralORFeome 1.0 (<http://pbildb1.univ-lyon1.fr/viralorfeome/index.php>), an open-access database and management system that provides an integrated set of bioinformatics tools enabling the potential capture of viral ORFs in the Gateway® recombinational cloning system. With the ViralORFeome database, Pellet *et al.* collected 545 ORF clones from \~238 viral genes in Gateway® entry vectors (pDONR207 or pDONR223). In addition, this study demonstrated the phenotypic expression of 67 viral genes transfected in HEK-293T cells [@B15]. Unfortunately, the overall progress of viral cloning has not progressed much beyond this due to the high cost of HT cloning and the difficulty in managing a large repository in a general lab [@B2], [@B15], [@B16].

Since the establishment of our laboratory and the DNASU Repository at Arizona State University, we have devoted significant effort in the HT cloning, construction, and maintenance of large DNA repositories (<http://dnasu.org>) [@B17], [@B18]. We have successfully created tens of thousands of sequence-verified ORFs in Gateway® recombination system, ranging from human to numerous pathogens and model organisms, such as *S. cerevisiae, P. aeruginosa, F. tularensis, V. cholerae and Y. pestis* [@B17]-[@B25]. The high flexibility of Gateway® system allows researchers to rapidly transfer these collections into any compatible expression vectors that fit their biological studies [@B26]-[@B36]. For example, using the *S. cerevisiae* plasmid collection, Zhu *et al.* purified 89 known and predicted *S. cerevisiae* transcription factor proteins, and profiled their DNA binding sites using ChIP-chip. More than 2.3 million gapped and ungapped 8-bp oligo sequences were identified, which allowed the re-annotation of *in vivo* TF binding targets, and examination of TFs\' potential effects on gene expression in about 1700 environmental and cellular conditions [@B23], [@B34]. Cooper *et al.* executed a genome-wide screen of 3,000 over-expressed yeast genes for the enhancers and suppressors of alpha-synuclein (αSyn). The misfolding of αSyn is associated with devastating neurodegenerative disorders such as Parkinson\'s disease (PD). 34 and 20 genes were identified to suppress and enhance αSyn toxicity, respectively. Rab1, the mammalian YPT1 homolog, was found to protect against αSyn-induced dopaminergic neuron loss in PD animal models [@B35]. We constructed human and pathogen Nucleic Acid Programmable Protein Arrays (NAPPA), with which we executed wide proteomics studies to find the antibody biomarkers that have potential value in the early detection of cancers, diabetes, autoimmune, and infectious diseases [@B26]-[@B33].

In this project, we plan to generate a plasmid collection that encodes all important human disease related viral proteins (\~6,000). The aim of our panviral proteome is to discover and characterize virus-host interactions and determine the association of these viral proteins with various human diseases. Similar to our human and pathogen collections, we will distribute these viral ORF constructs to the research community though DNASU (<http://dnasu.org>) [@B11], including the initial collection described in this paper containing 2,035 ORF clones in Gateway® entry vector (pDNOR221) and mammalian cell-free expression vectors (**Table [1](#T1){ref-type="table"}**). To illustrate the applications of this collection, we characterized the expression of ORF clones from three viral genomes utilizing human HeLa cell lysate-based cell-free expression system, western blot, and in-gel fluorescence. In addition, we studied rubella virus-host interactions using NAPPA arrays displaying 10,000 unique human proteins. We also analyzed the host serological response to coxsackievirus antigens using micro-fluidic multiplexed immunoassays. The explorations of our viral clone collection showed the highly efficient cell-free production of viral ORF proteins *in vitro*, identification of novel host-viral protein interactions, and a demonstration of how immune-dominant viral antigens could be used in the future for target drug development and detection of viral pathogen infection.

Materials and Methods
=====================

HT 2-Step PCR based cloning
---------------------------

We performed the HT 2-step PCR cloning as previously described [@B20]. Briefly, the reference sequences of viral ORFs were uploaded into our FLEXGene Laboratory information management system (LIMS) (<http://flex.asu.edu/FLEX>). The gene specific primers were designed by using a nearest-neighbor algorithm, with each primer containing a gene specific region and partial attB site. Universal primers were employed to provide the remaining full length attB site and further amplification of the target gene ORF. The start codon was normalized to ATG. The fusion and closed versions of the entry clones were created with and without removal of stop codon, respectively. Two-step PCR amplifications were performed in 96-well PCR plate using Tm of 60^o^C with Veriti® Thermal Cycler (Life Technologies, Grand Island, NY). The 2^nd^ PCR products were examined using E Gel® Electrophoresis System (Life Technologies, Grand Island, NY) (**Figure [2](#F2){ref-type="fig"}A**). Lastly, the PCR product was purified using PCR clean-up kit (MACHEREY-NAGEL, Bethlehem, PA).

*De novo*gene synthesis
-----------------------

### Gene design

First, attB1 (GGGGACAAGTTTGTACAAAAAAGCAGGCTCCACC) and the converse complementary oligo of attB2 (GACCCAGCTTTCTTGTACAAAGTGGTCCCC) were added to both ends of ORF reference sequences. The oligos with less than 60 base pairs (bp) were designed using oligoDesign3.0 (<http://54.235.254.95/cgi-bin/gd/gdOlapDes.cgi>), which can be separated into several blocks according to the length of target sequence [@B37], [@B38]. The oligos were ordered from Integrated DNA Technologies (Coralville, IA).

### Preparation of oligos and primers

All oligos were diluted into the stock concentration of 30 µM. The Template Oligo Mix (TOM1) was prepared by mixing 5 µL of inner oligos of each block with appropriate nuclease-free H~2~O to the final concentration of 2.5 µM. Primer Oligo Mix (POM1) was prepared by mixing 10 µL of the first and last oligos of each block with appropriate H~2~O to the final concentration of 10 µM. Primer Oligo Mix (POM2) was prepared by mixing 10 µL of the first and last oligo at the end of target ORF reference sequence with appropriate H~2~O to the final concentration of 10 µM. Gateway® universal forward and reverse primers (GUPs) were prepared at 10 µM[@B39].

### Gene synthesis

For the viral ORFs with longer sequences (\>700bp), the oligos need to be separated into multi-blocks by Gene Design 3.0, and undergo several assembly/amplification cycles to synthesize full-length reference sequence, e.g. HBV polymerase (**Figure [2](#F2){ref-type="fig"}B**). For the assembly of short oligos (≤ 60bp), each block was performed in a 50 µL reaction containing 1U iProof polymerase (BioRad, Hercules, CA) and 2.5 µL of a 250 µM TOM1 oligo mix. The PCR reaction was executed by starting at 98^o^C for 4 minute (min), followed by 25 cycles of 30 seconds (s) at 98^o^C for denaturation, 45s at 59^o^C for annealing, and 45s at 72^o^C for elongation. The amplification reaction was performed in a 50 µL PCR mix containing 1U iProof polymerase (Hercules, CA), 2 µL of assembled product, and 5 µL of POM1. The PCR reaction was executed with the same conditions as stated above, except 30 cycles was used. The amplified PCR products were ran and examined on an agarose gel with Ethidium Bromide and Bioline Hyperladder I (Bioline, Taunton, MA). Once the final assembled oligos were confirmed, they were purified using QIAquick Gel Extraction Kit (QIAGEN, Valencia, CA), and quantitated using a Nanodrop spectrophotometer (Wilmington, DE).

The assembly of seven blocks of HBV polymerase ORF sequence was performed in a 50 µL reaction containing 1U iProof polymerase and 50 ng of previously annealed oligos from each block. The second assembly PCR was performed the same as the first assembly reaction, but with a 1min elongation step. The second amplification reaction was performed in a 50 µL reaction containing 1 U iProof polymerase, 2 µL of previous assembled PCR product, and 5 µL of POM2 or UOP. The PCR was run under the same conditions as the first amplification reaction, but with a 2min elongation step. Once the full-length ORF reference sequence was synthesized, it was purified and the concentration was quantitated using a Nanodrop spectrophotometer (**Figure [2](#F2){ref-type="fig"}B**).

Construction of viral entry & expression clones
-----------------------------------------------

The procedure for the construction of entry and expression clones using the Gateway® system has been well described previously [@B14], [@B20], [@B23], [@B40]. Briefly, all purified PCR products and synthesized ORF sequences with attB1 and attB2 sites were cloned into a Gateway® entry vector (pDONR221) using BP Clonase (Life Technologies, Grand Island, NY). The clones were colony selected from agar plates and the ORF inserts were sequenced verified using our Automatic Clone Evaluation (ACE) software. For clones to be accepted in our viral gene plasmid collection, they must not contain truncations, frameshifts, or more than one amino acid change when compared to the reference sequence. In addition, any nucleotide change in the sequences of att-sites was also not accepted because it may cause failure of BP or LR reactions [@B20], [@B21].

To construct the collection of expression clones, sequence verified viral ORFs in entry vectors were transferred into mammalian cell-free expression vectors (pANT7_cGST, pJFT7_nHalo or pJFT7_cHalo) using LR Clonase (Life Technologies, Grand Island, NY). All solution transfers were executed by the Biomek FX automation workstation, and each cloning step was assigned a specific barcode which is tracked by the FLEXGene database throughout the cloning process.

Identification of host targets for rubella virus using NAPPA arrays
-------------------------------------------------------------------

Five NAPPA arrays containing 10,000 purified human cDNA plasmids were printed as previously described (\~2,000 ORFs/slide) [@B41]. To prepare NAPPA protein arrays, the slide was blocked with Superblock solution (Pierce, Rockford, IL) for 1hour (hr) at room temperature. The slide was then covered with a hybridization chamber and 160 μL of human HeLa cell lysate-based cell-free expression system (Thermo scientific, Rockford, IL) was injected into the chamber. The cell-free expression was performed at 30^o^C for 1.5 hrs, and then incubated at 15^o^C for 0.5 h. After briefly washing with PBST (PBS, 0.2%Tween 20), the resulting NAPPA protein array was blocked with cold PPI blocking buffer (1×PBS, 1%Tween 20 and 1% BSA, pH7.4) for 2 hrs at 4^o^C. In parallel, the rubella viral ORFeome proteins with C-terminal Halo tag (E1, E2, P90, capsid, and the mix of 150N and 150C) were produced in 170 μL human HeLa cell lysate-based cell-free expression system for 2 hrs at 30^o^C with 100 ng/μL of DNA.

To identify the host targets of rubella virus using our NAPPA arrays, the NAPPA human 10K arrays were incubated with the expressed rubella viral proteins in HeLa cell lysates for 16 hrs at 4^o^C. After washing three times with PPI wash buffer (PBS, 5 mM MgCl~2~, 0.5% Tween20, 1% BSA and 0.5% DTT, pH7.4), the protein-protein complexes formed on the NAPPA arrays were detected using 12.5 µM Alexa 660 conjugated Halo-ligand (Promega, Madison, WI) and incubated for 2hrs at 4^o^C. The fluorescent images were obtained with a Tecan\'s PowerScanner (Männedorf, Switzerland). The fluorescent signal intensity was quantitated using Array-Pro Analyzer (Media Cybernetics, Bethesda, MD).

Statistical analysis
--------------------

Prior to the statistical analysis, we examined all fluorescent microarray images for the spot shape, dust, and non-specific binding, in order to remove false positive signals. We then normalized the raw signal intensity of all spots to decrease the background variations from slide to slide. Normalization was performed by subtracting the background signals from non-specific binding of query proteins or Alexa660 labeled Halo ligand, which was estimated by the first quartile of the printing buffer-only control. Next, we calculated the normalized value using the raw signal intensity of each spot divided by the median background-adjusted value of all features on the array. Finally, we calculated the Z-score of each protein that was used for the target selection.

The selection of host target candidates of rubella virus was based on the following criteria: (1) Z-score ≥ 3, (2) Z-score ratio of query protein to Halo negative control ≥ 2, and (3) the targets have to meet previous criteria in two independent experiments.

Bioinformatics analysis
-----------------------

The protein annotation was performed with The UniProt (Universal Protein Resource) databases and PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification System. The rubella virus-host interaction network was built using Cytoscape (v2.6.3, available in <http://www.cytoscape.org>).

Co-localization verification of rubella virus capsid with host targets identified from NAPPA screens
----------------------------------------------------------------------------------------------------

The rubella virus capsid and its identified host targets were cloned into pCS Cherry DEST (Addgene) and pcDNA^TM^6.2/N-EmGFP/YFP-DEST (Life Technologies) vectors, respectively, using LR recombinant reactions. HeLa cells were transiently co-transfected with GFP-host targets and mCherry-capsid for 20 hrs. The cells were then fixed in 4% paraformaldehyde PBS and imaged using Zeiss LSM 510 inverted fluorescence confocal microscope (Zeiss) (100x objective) and images analyzed on ImageJ software.

Serological analysis of coxsackievirus proteins using micro-fluidic multiplexed immunoassays
--------------------------------------------------------------------------------------------

The micro-fluidic antigen channels were fabricated by covering an aminosilane coated glass slide with a customized PDMS mold embedded with 13 micro-channels. The PDMS mold was prepared by soft-lithography as previous descried (**Figure [6](#F6){ref-type="fig"}A**) [@B42]. The antigen coating of each channel was performed by injection of 5 µL expressed coxsackievirus proteins in human HeLa cell lysate-based cell-free expression system and incubated for 1h at room temperature. After washing three times with 0.2% PBST, the PDMS mold was removed and the antigen coated slide was blocked with 5% milk for 1 hr. The reaction channels were prepared by applying a new set of PDMS micro-fluidic channels that lay vertical to the antigen strips formed on the slide surface. In each reaction channel, the immobilized antigens were detected with an anti-Halo antibody and Alexa555 labeled goat anti-chicken IgG antibody (Life Technologies, Grand Island, NY) (**Figure [6](#F6){ref-type="fig"}A and [6](#F6){ref-type="fig"}B**).

The sera samples from human subjects were employed under the approval of IRB, with the age of subjects ranging from two to thirty-one years old. To test the serological response of the subjects, the sera were diluted 10 fold in the mix of *E.coli* and HeLa lysates, and incubated for 3 hrs. Then 5 µL of each diluted serum was injected into each reaction channel in duplicate. After a 1 hr incubation, the reaction channels were removed and the serological antibodies were captured by the antigens, and detected with Alexa647 labeled anti-human IgG secondary antibody (Jackson Immunotech, West Grove, PA). The resulting slide was scanned using Tecan microarray scanner, and the signal was quantitated in the same manner as the NAPPA arrays. The two-way non-hierarchical cluster analysis and the generation of heat map were performed using TM4: Microarray Software Suite (<http://www.tm4.org/>) based on complete linkage clustering method [@B43], [@B44].

Validation of coxsackievirus immune-dominant antigens using RAPID-ELISA
-----------------------------------------------------------------------

The immune-dominant antigens (VP0 and VP1) were further tested in duplicate with the same sera samples using RAPID-ELISA as previously described [@B33]. The VP0 and VP1 proteins were produced as described above. The signals of each antigen were calculated by subtracting out the background noise produced by serum antibodies in the well without viral proteins from the original read.

Results
=======

Construction of viral clones
----------------------------

We have developed a pipeline consisting of enterprise-class software and databases (FLEXGene LIMS and ACE) that are integrated with state-of-the-art robotics, including a DNA Factory (High-Res BioSolutions), BioMek FX liquid handler, and freezer storage system (Brooks Universal Biostore) [@B10], [@B17], [@B18], [@B45]-[@B48]. The streamlined integration of these systems has allowed us to manage our HT cloning projects, the DNASU plasmid repository, as well as millions of transactions in a seamless fashion (**Figure [1](#F1){ref-type="fig"}A**).

To construct our viral gene collection, we created a reference sequence library of viral genes downloaded from NCBI (<http://www.ncbi.nlm.nih.gov/pubmed/>) or ViralORFeome (<http://pbildb1.univ-lyon1.fr/viralorfeome/index.php>), and uploaded these reference sequences into our FLEXGene database (**Figure [1](#F1){ref-type="fig"}A**). FLEXGene enables us to track every construct during all stages of the cloning pipeline and storage. To capture these viral ORFs using the Gateway® cloning system, we employed two approaches: 1) HT 2-step PCR-based cloning and 2) *de novo*gene synthesis (**Figure [1](#F1){ref-type="fig"}**). The first approach has been frequently utilized in our lab over the past decade, and is used to clone the majority of viral genes with templates available [@B21], [@B23], [@B25], [@B40], [@B49]-[@B51] (**Figure [1](#F1){ref-type="fig"}B**). A representative image of 2-step PCR results is shown in **Figure [2](#F2){ref-type="fig"}A**.

However, the transcription of a small percentage of viral genes naturally contains frameshifts and stutters, which will not produce natural gene products when used in common experimental systems. These viral ORFs have multi-fragments with various lengths at different locations in their genomes, and cannot be simply amplified by the standard 2-step PCR based cloning. In addition, there are also some viruses whose complete templates are not easily acquired because of the regulatory restrictions, high contagious risk, *etc*. To address these issues, we utilized *de novo*gene synthesis as an alternative approach to produce the viral ORF according to their documented reference sequences (**Figure [1](#F1){ref-type="fig"}**). First, we designed a series of oligos (≤ 60bp) with chunk overlaps of 20bp for the target viral ORF using oligoDesign3.0 [@B38]. The attB1 and reverse complementary of attB2 were added to the 5\' end of the first oligo and at the end of the last oligo, respectively. Depending on the length of target sequence and user definition, the oligos can be allocated into multi-blocks. The oligos in each block were assembled and then amplified using assembly/amplification PCR (**Materials and Methods**). Several assembly/amplification cycles are necessary to produce the full-length viral ORFs (e.g., HBV polymerase). Each PCR product was ran on an agarose gel and examined to confirm successful synthesis (**Figure [2](#F2){ref-type="fig"}B**). After obtaining the complete ORF sequence, including the attB sites, the insert (i.e., ORF) can then be transferred into a Gateway® entry vector using the BP reaction. Next, the clones were colony selected from agar plates and the inserts were sequenced verified. The viral gene\' s expected (reference) sequence was compared to its actual sequence using ACE [@B46], and each discrepancy (e.g., silent or missense mutations, inframe or frameshift insertions or deletions) was recorded. Only insert sequences that passed our defined criteria were accepted into our panviral plasmid collection (**Materials and Methods**) [@B20], [@B21]. With these approaches, we have successfully cloned 830 viral genes into the Gateway® entry vector and three mammalian expression vectors (pANT7_cGST, pJFT7_nHalo or pJFT7_cHalo) to create a total of 2,035 ORF clones (**Table [1](#T1){ref-type="table"}**). In addition, we compared the ViralORFeome collection to ours, and found 65 genes in common (**Figure [3](#F3){ref-type="fig"}A**).

To demonstrate the applications of our panviral proteome collection, we utilized three viral clone sets to validate protein expression, examine virus-host interactions, and monitor detection of the host antibody response to coxsackievirus antigens.

Human cytomegalovirus (HCMV) ORFeome expression
-----------------------------------------------

In addition to sequence verifying all clones, we sought to demonstrate the production of protein of the correct size from a subset of these clones. We selected HCMV, which has a relatively large viral genome containing 165 ORFs, and transferred the ORFs to a mammalian cell-free expression vector (pANT7_cGST). The HCMV ORFeome was expressed *in vitro* using a human HeLa cell lysate-based cell-free expression system, the proteins were ran on a SDS-PAGE, and the proteins were transferred onto a nitrocellulose membrane. Each expressed protein has a C-terminal GST tag, and thus can be detected using a monoclonal mouse anti-GST antibody and HRP-labeled sheep anti-mouse IgG secondary antibody ([Additional file 1](#SM1){ref-type="supplementary-material"}: **Supplementary methods**). A representative image of western blot detection is shown in **Figure [3](#F3){ref-type="fig"}B**. By using visual inspection, most proteins showed a band on the nitrocellulose membrane at the expected locations of their molecular weight ([Additional file 1](#SM1){ref-type="supplementary-material"}: **Table S1**). These results indicate that all proteins from core and tegument classes, and most proteins from other classes (capsid, secreted, envelop and membrane) as well, were successfully expressed and detected using anti-GST antibody. We failed to detect protein for six of the 165 proteins for reasons that are not clear at this time.

As an alternative method for testing protein expression, we tested the expression of rubella viral ORFeome and coxsackievirus ORFs using in-gel fluorescence, in which the newly expressed protein of interest is covalently linked to a fluorescent tag ([Additional file 1](#SM1){ref-type="supplementary-material"}: **Supplementary methods**). The results indicate that all ORFs from these two viruses were successfully expressed and detected with Alexa660-labeled Halo-ligand ([Additional file 1](#SM1){ref-type="supplementary-material"}: **Figure S1** and **Figure S3**). In total we tested 182 proteins using one of these two methods, and 96.7% were detected at the correct size and at a level exceeding the background.

Rubella virus - host interactions
---------------------------------

Rubella virus has a small genome composed of single stranded (ss+) RNA that produces only five proteins (E1, E2, capsid, P90 and P150). To demonstrate the use of our panviral proteome collection in the study of virus-host interactions, we performed an unbiased screening of potential host targets for rubella viral proteins using NAPPA arrays displaying 10,000 unique human proteins. NAPPA is an advanced cell-free protein array with high-density and wide screening ability [@B52], [@B53]. More than 2,300 cDNA constructs are printed onto an aminosiliane coated slide and are transcribed/translated *in situ* at the time of experimentation using a mammalian cell-free expression system. The expressed proteins are captured/displayed with high affinity and specificity by an anchored anti-tag antibody printed together with the plasmid cDNA. NAPPA has been extensively used for applications such as antibody characterization, biomarker discovery, and detection of protein-protein interactions [@B26], [@B52]-[@B54].

The NAPPA protein arrays were probed with each viral protein bearing an N-terminal Halo tag that can be readily detected using fluorescein labeled Halo ligand if it binds to the host protein on the arrays ([Additional file 1](#SM1){ref-type="supplementary-material"}: **Figure S1**). A representative image of NAPPA screening is shown in **Figure [4](#F4){ref-type="fig"}A**. The image indicates that C1QBP/p32, a known host target of capsid [@B55], produced a more specific and bright fluorescence spot compared to neighboring proteins and Halo protein alone as a negative control. To select additional host target candidates, we employed the following criteria: (1) Z-score ≥ 3, (2) Z-score ratio of query to negative control ≥ 2, and (3) the targets should meet the previous two criteria in two independent experiments (**Materials and Methods**). Using these parameters as a cut-off, a total of 56 host proteins were identified as candidate targets of rubella viral proteins (**Table [3](#T3){ref-type="table"} and Figure [4](#F4){ref-type="fig"}**). Fourteen host proteins were further selected based on their Z-score and biological relevance and validated using an independent *in vitro* bead based pull-down assay ([Additional file 1](#SM1){ref-type="supplementary-material"}: **Supplementary methods**). Among them, six viral proteins (C1QBP, CHCHD2, ZnT8, GPR1, Rab25 and Arl8A) were confirmed using *in vitro*based pull-down assays (**Figure [4](#F4){ref-type="fig"}C**). In addition, we transiently co-transfected HeLa cells with the mCherry tagged capsid and four GFP tagged host targets for 20 hrs, and imaged the intracellular localization of both constructs using confocal microscopy. Besides the known binding protein of C1QBP[@B55], we found three novel host proteins,CHCHD2, DUSP26 and NKFB1, were also co-localized with the capsid in HeLa cells (**Figure [5](#F5){ref-type="fig"}**).

Host serological response to coxsackievirus proteins
----------------------------------------------------

As a member of Enterovirus family, Coxsackievirus B4 is one of the six serotypes of coxsackievirus group B. The coxsackievirus B infection is common in the summer and autumn in the areas of temperate climates and all year in tropics. Adolescents less than 16 years old are the susceptible population, but infection has been also observed in adults [@B56]. To investigate whether coxsackievirus proteins can serve as antigens inducing a humoral response in the blood of people with potential coxsackievirus infection, we performed a serological test using micro-fluidic multiplexed immunoassays. The experimental setup is shown in Figure [6](#F6){ref-type="fig"}A. First, we coated 11 micro-fluidic channels with unpurified HeLa cell lysate expressing each of 10 coxsackievirus antigens, and one with HeLa cell lysate alone as negative control (n.c). The immobilization of these antigens (rows) was confirmed using anti-Halo tag antibody (columns). These results indicate that all 10 antigens were successfully coated on their corresponding channels and are observed as specific red fluorescent signals, which do not exist in the channel coated with only HeLa lysates (n.c.) (Figure [6](#F6){ref-type="fig"}B). Further signal quantification shows that the signal intensity of coated coxsackievirus antigens is higher than that of the negative control plus three folds of the standard deviations with an average variation of 26.3% (Figure [6](#F6){ref-type="fig"}C).

To detect the serological antibodies, we randomly selected 11 sera samples regardless of their disease background. The prepared antigen array was incubated using 5 µL of 1:10 diluted human serum in each channel and the detection was performed using an Alexa647 labeled anti-human IgG secondary antibody. VP1 and VP0 showed responses in the largest number of subjects, each showing responses in 50% of the subjects; although, VP1 had the strongest signal intensity (Figure [6](#F6){ref-type="fig"}D). Notably, there was not complete overlap in the responses to these two antigens, with some subjects responding to one but not the other. We did not observe any signal in the n.c. from either antigens or sera samples (\#00), which demonstrate the specificity of these antibodies. The separation between VP0 and VP1 responders was illustrated by performing a two-way non-hierarchical cluster analysis and populating a heat-map (Figure [6](#F6){ref-type="fig"}E). Most of antigens (VP3, 2C, 2A, VP4, 3C and RP) did not show any response in these sera samples. The immune-dominant antigens of VP0 and VP1 were further validated using ELISA with the same sera samples (Figure [6](#F6){ref-type="fig"}F). Without clinical histories and with such a small sample size, we cannot draw specific conclusions regarding immunoproteomic responses to coxsackievirus B infections. Nevertheless, these data illustrate the rapid feasibility of using a microfluidic approach to address this question.

Discussion
==========

During the past decade we have developed a HT cloning and management pipeline, which integrates customized software, databases, and state-of-art robotics (**Figure [1](#F1){ref-type="fig"}**). More specifically, the FLEXGene database is used to track the overall cloning pipeline starting from the uploading of reference sequences, through transferring ORFs into the Gateway® entry vector and destination vectors, sequence verification, preparation of glycerol stock, to the end with the submission of final information and plasmid samples to DNASU [@B17], [@B18]. ACE automates the sequence evaluation process, enabling the management of hundreds of clones simultaneously by interacting with FLEXGene and comparing each clone\'s actual and reference sequences using defined criteria to find discrepancies [@B20], [@B21], [@B46]. DNASU is a central repository of plasmids which stores over 200,000 plasmids from more than \~800 organisms [@B10], [@B14]. These plasmids are easily searchable through the website <http://dnasu.org>, and DNASU operations distribute these plasmids to researchers worldwide upon request. Each plasmid is stored in a 2-D barcoded tube as a glycerol stock in a fully automated -80°C Brooks Biostore freezer allowing fast retrieval upon ordering. These collections have demonstrated their great value in numerous biological studies in basic research, cancer, autoimmune and infectious disease [@B26], [@B27], [@B31], [@B34], [@B35], [@B52], [@B53], [@B57]-[@B60].

In this work, we have integrated viral cloning into the pipeline that has already been extensively used for human and bacterial gene cloning. The difference from previous non-viral cloning is that we employ gene synthesis for those viral ORFs without templates, or whose reference polypeptide sequence is not contiguous in the genome (**Table [2](#T2){ref-type="table"}**). The cost of gene synthesis is much higher than the 2-step PCR-based approach because of the high cost of the oligos required for synthesis. Even with local synthesis of the oligos using an oligo synthesizer, which would reduce the cost, this method is likely to be more expensive than the PCR approach. By using the GeneDesign 3.0 and the protocol we developed, we successfully obtained 100% of the genes we attempted to synthesize, with DNA lengths ranging from 200 bp to 3,000 bp (**Figure [2](#F2){ref-type="fig"}B**).

The successful translation of these viral clones to proteins is the key to study virus-host interactions, as well as their association with human diseases [@B2]. To illustrate this approach, we chose three viruses, two (HCMV and rubella virus) with complete ORFeomes and one (coxsackievirus) with 10/12 of ORFeome clones. We tested this virus-host interaction using a human HeLa cell lysate-based cell-free expression system. We selected this human cell-free expression system because of its inherent advantages of high efficiency and effectiveness, and its ability to produce membrane and large size proteins [@B61], [@B62]. It has been recently employed in our lab in the fabrication of high-density NAPPA arrays [@B62], [@B63]. With this system, we found 96.4% HCMV and 100% of rubella virus and coxsackievirus ORFeomes were successful expressed (**Figure [3](#F3){ref-type="fig"}B,**[Additional file 1](#SM1){ref-type="supplementary-material"}: **Figure S1, Figure S3 and Table S1**). This corresponds favorably to the previous results using wheat-germ and rabbit reticulocyte lysate cell-free expression systems [@B52], [@B64]. These results demonstrate the ease and efficiency of our viral collection in the production of viral proteins by combination with human cell-free expression system *in vitro*.

The comprehensive collection of viral ORFeome clones enables us to study virus-host interaction from a systematic standpoint, and reveals new host cellular proteins that might be hijacked by viruses to alter host cellular processes. Rubella virus is the causative agent of German measles in children and congenital rubella syndrome when the virus infection occurs during the first trimester of pregnancy. In addition, it can cause polyarthralgia, a complication of rubella infection in adult women. Humans are the only known host of rubella virus, and the development of effective vaccines have significantly reduced the incidence in developed countries [@B65]. However, the molecular mechanisms of rubella infection/replication in the host, and the causation of congenital rubella syndrome are still unclear. There have been a few host proteins, C1QBP/p32, Bax and RABP, identified to be involved in host-rubella interactions [@B55], [@B66]-[@B68]. In this work, we screened all rubella viral proteins on NAPPA arrays with 10,000 human proteins, and identified 55 novel candidate host targets in addition to the three previously identified interactors [@B66]-[@B68]. Six viral proteins were selected and validated using *in vitro* based pull-down, and four viral proteins were used in *in vivo*based cellular co-localization analysis (**Figure [4](#F4){ref-type="fig"}C and Figure [5](#F5){ref-type="fig"}**). In our intracellular localization studies, we found that the rubella proteins locate to different sub-cellular locations (i.e. membrane (36%), nucleus (19%), cytoplasm (16%), secreted (5%), mitochondrion (3%), endoplasmic reticulum (2%) and others (14%)) (**Figure [4](#F4){ref-type="fig"}B,**[Additional file 1](#SM1){ref-type="supplementary-material"}: **Figure S2 and Table [3](#T3){ref-type="table"}**).

With all of these identified targets, we constructed the first systematic rubella virus-host interaction network, and analyzed the biological processes of these host targets associated in host cell (**Figure [4](#F4){ref-type="fig"}B**). The annotation results indicate that four capsid targets, C1QBP, Bax, RSF1 and NFKB1, and two P150 targets, ATF3 and IFNA13, are involved in apoptosis, which is consistent with the cytotoxicity caused by rubella virus [@B68], [@B69]. Other host targets of E1, E2, capsid and P150 are associated with transport, transcription/translation and metabolic processes. P90 has the fewest targets associated with metabolic processes [@B55], [@B70]*.*

E1 is the main surface viral protein that might co-opt the host G-protein-coupled receptors and activate their downstream pathways through GPR1 and GRP62 [@B71], [@B72]. The functions of E2 and P90 are largely unknown; although, it was found that the glycosylation of E2 could alter the specific membrane fusion using rubella virus JR23 strain [@B73]. Here, we provide new evidence that E2 and P90 may participate in the viral attachment and fusion between viral envelope and the endosomal membrane through membrane proteins of GNAZ, TMEM106B and GPR27, and regulate the cytoskeleton by RhoJ [@B72], [@B74]. In addition, E2 and P150 may be involved in the viral vesicle transportation through Rab and Arl GTPases of Rab25 and Arl8A [@B75], [@B76]. Viral capsid is the only protein that has been found with multi-functions, which include the regulation of viral replication and acting as a potent inhibitor of host cell apoptosis and protein synthesis [@B55], [@B66], [@B68]. Here we found, besides C1QBP, that the capsid may also interact with other host cell proteins in membranes, cytoplasm, mitochondria, endoplasmic reticulum, Golgi, and nucleus, and can include such host proteins as PLXNC1, CHCHD2, BET1, NFKB1, *etc.* [@B77], [@B78]. These results need additional confirmation with cell-based *in vivo* assays; however, these results give us a first glimpse of a comprehensive view of rubella-virus interactions by physical interactions. In future functional studies, these results may reveal important host proteins involved in the regulation of rubella viral invasion, transportation, and replication.

Most of coxsackievirus B4 infection exists as asymptomatic, undifferentiated febrile illness, or mild upper respiratory symptoms. But this virus can induce a wide range of diseases such as aseptic meningitis, encephalitis, pleurodynia, myocarditis, and pericarditis [@B79]-[@B82]. The development of a rapid serological test and vaccine would be a valuable tool in the early diagnosis and prevention of coxsackievirus [@B83]. In this work, we tested the antigenicity of coxsackievirus proteins using a micro-fluidic multiplexed immunoassay which can detect up to 24 antigens simultaneously with only 0.5 µL undiluted human serum [@B42]. We found the unpurified coxsackievirus proteins in HeLa cell lysates can be coated on the amino modified slide surface and detected with anti-Halo tag antibody (Figure [6](#F6){ref-type="fig"}B and [6](#F6){ref-type="fig"}C). The uses of unpurified cell-free produced proteins have been frequently employed in the fabrication of pathogen microarrays to screen and validate antibody biomarkers of infectious diseases [@B84]-[@B87]. The key step of this approach is to block the non-specific bindings of serum antibodies to background proteins originating from HeLa cell lysates or *E.coli* during DNA preparation [@B88]. Here, we found by blocking the sera using a mix of HeLa cell and *E.coli* lysates in 5% milk, the background was largely decreased and the signal to noise ratio was improved. The screening of 11 sera samples using microfluidic multiplexed immunoassay and ELISA, revealed that VP0 and VP1 might be two dominant antigens which are recognized by the host immune system (Figure [6](#F6){ref-type="fig"}D-F). The differential antigenicity of VP0 and VP1 implies that these two antigens might be potential markers that have complementary value in the diagnostics of coxsackievirus infection as well as development of a new vaccine. However, further experiments with much larger well-characterized clinical sample sets are needed to establish this relationship.

Conclusion
==========

In this work, we describe the initial effort of our panviral proteome with the collection of 2,035 viral OFR clones from 30 viral species. We demonstrated the uses of our viral collection in the highly efficient production of viral proteins using cell-free expression system *in vitro*, global identification of host targets for rubella virus using NAPPA protein arrays, and detection of host serological response using micro-fluidic multiplexed immunoassays. In the future, we will be continuing to collaborate with other labs to extend our collection, study viral invasion/evasion mechanisms, develop novel diagnostic tools, and drugs for the therapeutic treatment.
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![High-throughput viral gene cloning and repository construction. (A) The pipeline of high-throughput viral gene cloning, repository management and clone distribution. (B) The strategies of viral gene cloning and repository construction.](thnov04p0808g001){#F1}

![The representative images of viral gene cloning by 2-step PCR and *de novo* gene synthesis. (A) Examination of the 2^nd^ PCR products from PCR-based cloning in E-gel. Here, 72 HSV1 ORFs amplified from their templates are shown as 9 columns × 8 rows. (B) Synthesis of HBV polymerase ORF using gene synthesis. The total 84 oligos (\~60bp/oligo) were designed and automatically allocated into seven blocks by Gene Design 3.0. The oligos before (\~60 bp/oligo) and after assembly (\~400 bp/block) are shown at their expected sizes in an agarose gel. These assembled blocks were further annealed into a full-length HBV polymerase with the size of 2592bp, including attB sites.](thnov04p0808g002){#F2}

![Panviral proteome has the largest viral ORF clone collection to date. (A) Comparison of the number of viral ORF clones shared by panviral proteome and viralORFeome collections. (B) Examination of the expression of HCMV ORFeome clones from panviral proteome collection using western blot. The detection of GST-protein was performed using mouse anti-GST antibody and HRP labeled sheep anti-mouse IgG antibody. The band of expressed proteins at their expected sizes was visually inspected and the results is listed in [Additional file 1](#SM1){ref-type="supplementary-material"}: Table S1.](thnov04p0808g003){#F3}

![Rubella virus - host interactions. (A) The representative images show the host target identified for rubella virus using NAPPA arrays displaying 10,000 human proteins. The color of the microarray spot from blue to red corresponds to the fluorescent signal from weak to strong. (B) Rubella virus - host interaction network. The host proteins with red letters are the previous known targets and solid lines indicate independent validation. The annotation of biological process was performed by the PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification System. The interaction network was constructed with Cytoscape. (C) Selective validation of host targets using bead-based pull-down assays. PD: Pull-down, WB: Western blot. Halo protein is used as a query control in both microarray and pull-down assays.](thnov04p0808g004){#F4}

![Co-localization analysis of rubella virus capsid and its host targets in HeLa cells. The co-transfection of HeLa cells were executed for 20 hrs using the constructs of mChery tagged capsid (Red) and GFP tagged host targets (Green). The cells were fixed in 4% paraformaldehyde and imaged using confocal fluorescence microscopy. The nucleus was stained with Hoechst dye and shown as blue. Scale bar, 5µm.](thnov04p0808g005){#F5}

![Immunological profiling of human serological response to coxsackievirus antigens. (A) The work flow of micro-fluidic multiplexed immunoassays, (B) The fluorescent image of coxsackievirus protein expression and detection using anti-Halo antibody, (C) The fluorescent signal intensity of viral proteins coated in the antigen channels (left, y-axis) and the coefficient variations from channel to channel (right, y-axis), (D) and (E) are the fluorescent images and the heatmap of serological antibody profiling using micro-fluidic multiplexed immunoassays, respectively. 00 is buffer alone and 01-11 are the human sera samples. n.c. is HeLa cell lysate as negative control, and (F) is the validation of immune-dominant antigens (VP0 and VP1) using RAPID-ELISA.](thnov04p0808g006){#F6}

###### 

List of viral ORF clones that have been collected.

  ----------------------------------------------------------------------------------------------------------------------
  Name                                       Abbre.   Family             Entry vector   Mammalian cell-free\   
                                                                                        expression vectors     
  ------------------------------------------ -------- ------------------ -------------- ---------------------- ---------
  Epstein-Barr virus                         EBV      Herpesvirinae      73             89                     89

  Hepatitis B Virus                          HBV      Hepadnaviridae                    7                      7

  Human papillomaviruses, type5              HPV5     Picobirnaviridae   \-             4                      4

  Human papillomaviruses, type6              HPV6     Picobirnaviridae   \-             5                      5

  Human papillomaviruses, type8              HPV8     Picobirnaviridae   \-             3                      3

  Human papillomaviruses, type11             HPV11    Picobirnaviridae   \-             5                      5

  Human papillomaviruses, type16             HPV16    Picobirnaviridae   \-             3                      8

  Human papillomaviruses, type18             HPV18    Picobirnaviridae   \-             4                      8

  Human papillomaviruses , type33            HPV33    Picobirnaviridae   \-             4                      4

  Kaposi\'s sarcoma-associated herpesvirus   KSHV     Herpesviridae      67             67                     67

  Human cytomegalovirus                      HCMV     Herpesvirinae      \-             165                    165

  Herpes simplex virus type 1                HSV1     Herpesviridae      94             94                     94

  Adenovirus                                          Adenoviridae       \-             16                     16

  Simian virus 40                            SV40     Polyomaviridae     6              6                      6

  Varicella-zoster virus                     VZV      Herpesviridae      66             84                     94

  Vaccinia                                   VACV     Poxviridae                        167                    167

  Human endogenous retrovirus K              HERK     Retroviridea       4              4                      4

  Influenza A virus, H1N1                             Orthomyxoviridae   \-             10                     10

  Influenza A virus, H3N2                             Orthomyxoviridae   \-             10                     10

  Chikungunya virus                          CHIKV    Togaviridae        9              9                      9

  Sindbis virus                              SINV     Togaviridae        9              9                      9

  Semliki Forest virus                       SFV      Togaviridae        9              9                      9

  Yellow fever virus                         YFV      Flaviviridae       11             11                     11

  Tioman virus                                        Paramyxoviridae    3              3                      3

  Measles virus                              MeV      Paramyxoviridae    5              5                      5

  Coxsackievirus                                      Picornaviridae     \-             12                     12

  Mumps virus                                MuV      Paramyxoviridae    \-             8                      8

  Rubella virus                              RUBV     Togaviridae        \-             5                      5

  Rotavirus A                                RV-A     Reoviridae         \-             12                     12

  **Number**                                                             **356**        **830**                **849**

  **Total number**                                                                      **2035**               
  ----------------------------------------------------------------------------------------------------------------------

###### 

Compare the PCR-based cloning and *de novo*gene synthesis.

                       PCR-based cloning   *De novo*gene synthesis
  -------------------- ------------------- -----------------------------------------------------------------------------------------
  Target viral gene    With template       Without template or the viral ORF reference sequence is not contiguous in the genome
  Safety requirement   High                Low
  Throughput           High                Low
  Procedure            2-step PCRs         Depending on the length of target ORF, and may need multi-assembly/amplification cycles
  Time                 \~ 6 hours          \~ 6 hours /cycle
  Cost                 Low                 High, but can be significantly alleviated by synthesizing oligos in the lab

###### 

List of host target candidates for rubella virus identified from NAPPA arrays.

  No.                  Host protein   Gene ID   Description                                                                       Protein class                                          Cellular location                               Z-score   
  -------------------- -------------- --------- --------------------------------------------------------------------------------- ------------------------------------------------------ ----------------------------------------------- --------- ------
  **E1 targets**                                                                                                                                                                                                                                   
  1                    ZnT8           169026    Zinc transporter 8                                                                Transporter                                            Cell membrane                                   0.3       6.6
  2                    CCT8L2         150160    Putative T-complex protein 1 subunit theta-like 2                                 Chaperonin                                             Cytoplasm                                       -0.2      6.3
  3                    LRRC58         116064    Leucine-rich repeat-containing protein 58                                         Growth factor receptor                                 n.a.                                            -0.4      4.9
  4                    GPR62          118442    Probable G-protein coupled receptor 62                                            G-protein coupled receptor                             Cell membrane                                   0.4       4.7
  5                    MEIS2          4212      Homeobox protein Meis                                                             Homeobox transcription factor                          Nucleus                                         0.5       4.6
  6                    ZSCAN5A        79149     Zinc finger and SCAN domain-containing protein 5A                                 KRAB box transcription factor                          Nucleus                                         -0.1      3.8
  7                    BANK1          55024     B-cell scaffold protein with ankyrin repeats                                      n.a.                                                   n.a.                                            0.3       3.5
  8                    GPR1           2825      G-protein coupled receptor 1                                                      G-protein coupled receptor                             Membrane                                        -0.5      3.5
  **E2 targets**                                                                                                                                                                                                                                   
  9                    ANXA11         311       Annexin A11                                                                       Transfer/carrier protein                               Cytoplasm; Melanosome; Nucleus                  0.9       9.4
  10                   FAM84A         151354    Protein FAM84A                                                                    Acyltransferase                                        n.a.                                            -0.4      7.8
  11                   RAB25          57111     Ras-related protein Rab-25                                                        Small GTPase                                           Cell membrane; Lipid-anchor; Cytoplasmic side   0.2       5.4
  12                   RHOJ           57381     Rho-related GTP-binding protein RhoJ                                              Small GTPase                                           Cell membrane; Lipid-anchor; Cytoplasmic side   -0.2      5.3
  13                   SMARCC1        6599      SWI/SNF complex subunit SMARCC1                                                   Transcription cofactor                                 Nucleus                                         0.2       5.0
  14                   BMPR1A         657       Bone morphogenetic protein receptor type-1A                                       Serine/threonine protein kinase receptor               Membrane                                        0.6       4.5
  15                   STAM2          10254     Signal transducing adapter molecule 2                                             Serine/threonine protein kinase receptor               Cytoplasm                                       -0.1      4.3
  16                   RNPEP          6051      Aminopeptidase B                                                                  Transporter, Membrane traffic protein                  Secreted                                        -0.3      3.7
  17                   MGAT1          4245      Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1               Glycosyltransferase                                    Golgi apparatus membrane                        0.1       3.7
  18                   TCEB3          6924      Transcription elongation factor B polypeptide 3                                   Transcription factor                                   Nucleus                                         -0.7      3.5
  19                   GNAZ           2781      Guanine nucleotide-binding protein G(z) subunit alpha                             Heterotrimeric G-protein                               Membrane; Lipid-anchor                          0.5       3.4
  **P90 targets**                                                                                                                                                                                                                                  
  20                   TMEM106B       54664     Transmembrane protein 106B                                                        n.a.                                                   Late endosome membrane                          -0.1      7.7
  21                   LCE2B          26239     Late cornified envelope protein 2B                                                Structural protein                                     n.a.                                            -0.2      4.4
  22                   GPR27          2850      Probable G-protein coupled receptor 27                                            G-protein coupled receptor                             Membrane                                        0.4       3.2
  **Capsid targets**                                                                                                                                                                                                                               
  23                   ASPSCR1        79058     Tether containing UBX domain for GLUT4                                            n.a.                                                   Endomembrane system                             0.3       7.9
  24                   PQLC3          130814    PQ-loop repeat-containing protein 3                                               n.a.                                                   n.a.                                            0.3       7.1
  25                   PPP2R5D        5528      Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform   Protein phosphatase                                    Cytoplasm; Nucleus                              -0.5      5.4
  26                   HIST1H2AD      3013      Histone H2A type 1-D                                                              n.a.                                                   Nucleus; Chromosome                             0.2       4.5
  27                   RSF1           51773     Remodeling and spacing factor 1                                                   Acetyltransferase, Transcription factor                Nucleus                                         0.0       4.4
  28                   C1QBP          708       Complement component 1 Q subcomponent-binding protein                             Antibacterial response protein complement component    Mitochondrion matrix; Nucleus                   -0.3      4.3
  29                   NFKB1          4790      Nuclear factor NF-kappa-B p105 subunit                                            Transcription factor                                   Nucleus; Cytoplasm                              -0.7      4.3
  30                   SYT6           148281    Synaptotagmin-6                                                                   Membrane trafficking regulatory protein                Cytoplasmic vesicle                             0.5       4.2
  31                   BET1           10282     BET1 homolog                                                                      SNARE protein                                          Golgi apparatus membrane                        0.7       4.1
  32                   DULLARD        23399     CTD nuclear envelope phosphatase 1                                                Serine/threonine protein phosphatase                   Endoplasmic reticulum membrane                  -0.7      3.9
  33                   DUSP26         78986     Dual specificity protein phosphatase 26                                           Protein phosphatase                                    Cytoplasm; Nucleus; Golgi apparatus             -0.5      3.8
  34                   PLEK           5341      Pleckstrin                                                                        Cytoskeletal protein                                   n.a.                                            -0.6      3.5
  35                   PLXNC1         10154     Plexin-C1                                                                         Tyrosine protein kinase receptor, Protein kinase       Membrane                                        -0.3      3.4
  36                   CHCHD2         51142     Coiled-coil-helix-coiled-coil-helix domain-containing protein 2, mitochondrial    n.a.                                                   Mitochondrion                                   0.0       3.3
  37                   SLC1A5         6510      Neutral amino acid transporter B(0)                                               Cation transporter                                     Membrane                                        -0.4      3.1
  38                   SLC16A7        9194      Monocarboxylate transporter 2                                                     Transporter                                            Membrane                                        -0.5      3.1
  **P150 targets**                                                                                                                                                                                                                                 
  39                   ATF3           467       Cyclic AMP-dependent transcription factor ATF-3                                   CREB transcription factor                              Nucleus                                         3.9       11.7
  40                   RHES           23551     GTP-binding protein Rhes                                                          Small GTPase                                           Cell membrane; Lipid-anchor                     3.3       9.3
  41                   CKM            1158      Creatine kinase M-type                                                            Amino acid kinase                                      Cytoplasm.                                      0.0       7.0
  42                   APOA1          335       Apolipoprotein A-I                                                                Transporter                                            Secreted                                        2.0       6.4
  43                   TMEM140        55281     Transmembrane protein 140                                                         n.a.                                                   Membrane                                        -0.1      6.0
  44                   PPIL5          122769    Leucine-rich repeat protein 1                                                     Growth factor receptor, adenylate cyclase              n.a.                                            0.0       5.6
  45                   B3GNT1         11041     N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase                    Glycosyltransferase                                    Golgi apparatus membrane                        1.8       5.6
  46                   POP4           10775     Ribonuclease P protein subunit p29                                                Endoribonuclease                                       Nucleus                                         1.8       5.5
  47                   SDCCAG3        10807     Serologically defined colon cancer antigen 3                                      n.a.                                                   Cytoplasm                                       1.6       5.1
  48                   SSX4B          548313    Protein SSX4                                                                      Transcription factor                                   n.a.                                            1.2       4.1
  49                   KIAA1310       55683     KAT8 regulatory NSL complex subunit 3                                             n.a.                                                   Nucleus                                         0.9       4.0
  50                   IFNA13         3447      Interferon alpha-1/13                                                             Interferon superfamily                                 Secreted                                        0.4       3.9
  51                   CELA2B         51032     Chymotrypsin-like elastase family member 2B                                       Serine protease                                        Secreted                                        0.4       3.5
  52                   ARL8A          127829    ADP-ribosylation factor-like protein 8A                                           Small GTPase                                           Late endosome membrane; Lysosome membrane       0.2       3.4
  53                   SNIP1          79753     Smad nuclear-interacting protein 1                                                Transporter                                            Nucleus                                         0.2       3.4
  54                   EIF4A1         1973      Eukaryotic initiation factor 4A-I                                                 RNA helicase, translation initiation factor helicase   n.a.                                            0.7       3.3
  55                   SULF2          55959     Extracellular sulfatase Sulf-2                                                    Hydrolase                                              Endoplasmic reticulum                           0.4       3.3
  56                   MRPL54         116541    39S ribosomal protein L54, mitochondrial                                          n.a.                                                   Mitochondrion                                   0.1       3.2

\*n.a.: not available.
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